Literature DB >> 9470318

The pharmacokinetics of oral rifampicin in AIDS patients.

S Jaruratanasirikul1.   

Abstract

Previous studies in AIDS patients have shown that the peak serum concentration of rifampicin at 2 hours after administration are below normal ranges. These may be due to malabsorption of the drug resulting in therapeutic failure. However, there is no published data to demonstrate the pharmacokinetics of rifampicin in these AIDS patients. Therefore, the aim of this study was to provide such data. Eight AIDS patients with tuberculosis participated in this study. All patients were scheduled to receive oral rifampicin 600 mg once daily in the morning on an empty stomach. Rifampicin pharmacokinetics were studied on day 14. The mean Cmax was 9.81 +/- 4.41 ug/ml. The mean Tmax was 2.25 +/- 0.71 h. The mean AUC0-24 was 60.25 +/- 36.88 ug.h/ml. The results of our study did not confirm the previous studies. The absorption of rifampicin in most of our AIDS patients were not reduced and delayed. Therefore, rifampicin dosage adjustment for Thai patients may not be necessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9470318

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  8 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations.

Authors:  J E Conte; J A Golden; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.

Authors:  John E Conte; Jeffrey A Golden; Juliana E Kipps; Emil T Lin; Elisabeth Zurlinden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Authors:  Alper Daskapan; Lusiana R Idrus; Maarten J Postma; Bob Wilffert; Jos G W Kosterink; Ymkje Stienstra; Daniel J Touw; Aase B Andersen; Adrie Bekker; Paolo Denti; Agibothu K Hemanth Kumar; Kidola Jeremiah; Awewura Kwara; Helen McIlleron; Graeme Meintjes; Joep J van Oosterhout; Geetha Ramachandran; Neesha Rockwood; Robert J Wilkinson; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

8.  Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.

Authors:  Hendrik Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter Roderick Donald
Journal:  BMC Med       Date:  2009-04-22       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.